Medpace Holdings, Inc. (MEDP)

Medpace Holdings, Inc. (MEDP) stock has shown strong upward momentum, with a 71.46% increase over the last 12 months and a 109.74% gain over the past six months, reaching a new 52-week high of $626.26 in November 2025, influenced by strong financial performance. In October 2025, Medpace reported impressive third-quarter 2025 earnings, surpassing market expectations. Despite the positive stock performance, there have been instances of insider selling.

Medpace Holdings, Inc. experiences strong and consistent demand for its clinical research services, evidenced by a high request-for-proposal (RFP) volume and a favorable book-to-bill ratio of 1.20 in Q3 2025. No explicit seasonality in demand for Medpace's products and services has been identified.

Medpace Holdings, Inc. (MEDP) is a global clinical research organization (CRO) providing outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. It operates in the healthcare sector, specifically in diagnostics and research, offering a full suite of services covering all phases of clinical trials. Its services include project management, regulatory affairs, data management, clinical monitoring, and post-market clinical support. Medpace specializes in therapeutic areas such as oncology, cardiology, metabolic diseases, CNS, and antiviral and anti-infective.

Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio, USA, and has a significant international presence, operating in over 40 countries across North America, Europe, Asia, South America, Africa, and Australia.

Medpace's brand reputation in the past year appears strong, driven by its consistent financial performance and growth. The company has demonstrated impressive revenue and net income increases, with Q3 2025 revenue up 23.7% year-over-year and net new business awards increasing by 47.9%. There have been no widely reported events in the past year that have negatively impacted Medpace Holdings, Inc.'s brand reputation.

Medpace Holdings, Inc. has a high level of institutional ownership, with approximately 94.58% of its shares held by institutions, including BlackRock, Inc., Vanguard Group Inc, Aqr Capital Management Llc, Wasatch Advisors Inc, and State Street Corp. Insider ownership stands at approximately 3.9%.